Unichem Laboratories cash flow

·Pharma & HealthChart ›
Latest FY26
Cash from operations
₹3.6cr−₹7.0 cr in FY25
Capital spending
₹123cr−10.4% on FY25
Free cash flow
−₹119cr−₹144 cr in FY25
Cash from financing
₹1.9cr−99.0% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—125125113113
—0.00.00.03.4
—31.521.022.717.3
—−5.30.00.00.0
—−2.30.7−6.4−9.0
—0.82.13.11.0
—−5.94.0−1.02.7
—56.10.11264.5
—−273−1.0−69.6−0.0
Changes in working capital
—13.8−252−79.4−25.0
—−20.9−39.0−25.1−124
—0.00.00.00.0
—0.00.02.00.0
—0.00.0−33.80.0
—0.00.040.50.0
—−201−2.48.7119
—0.00.0−7.10.0
—0.00.0−8.40.0
Cash from operating activities
350292155−61.7−176
—−281−14285.4104
—11.212.323.8−72.4
—0.0−2.9−0.7−0.5
—0.00.0−0.0−0.0
—7.616.46.412.2
—3.6−7.016.7−85.1
Cash from investing activities
—12313722.544.3
—2832.28.96.4
—0.01.465.2237
—0.084.50.00.0
—4.00.00.00.0
—0.00.00.00.0
—5.61.70.60.9
—22.9−24.6−1.83.3
—192−24150.4203
Cash from financing activities
—75.32350.00.0
—41.925.778.533.4
—6.35.95.43.4
—24.919.622.216.3
—0.00.30.228.3
—−0.40.00.00.0
—1.9184−106−81.3
—198−64.5−39.236.4
—2.3−0.76.41.8
—200−65.2−32.838.2
———151184
Reference items
229184265100−45.6
9.9%8.4%12.6%5.9%−3.4%
−119−119−144−5.9−129
—−10646.9−106—
−₹16.96−₹16.96−₹20.51−₹0.83−₹18.38
—0.01×−0.05×−0.24×0.42×
—7.616.46.412.2
—24.919.622.216.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health
₹ CrorePeersGUFICBIORPGLIFEGUJTHEMSMSPHARMAORCHPHARMAINDSWFTLABSOLARAFDCMcap ₹3,441 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation113.4113.2124.6125.1—
+ Impairment Loss / (Reversal)3.40.00.00.0—
+ Finance Costs17.322.721.031.5—
+ Interest Income0.00.00.0-5.3—
+ Fair Value (Gains) / Losses-9.0-6.40.7-2.3—
+ Share-based Payments1.03.12.10.8—
+ Unrealised FX (Gain) / Loss2.7-1.04.0-5.9—
+ Other Non-cash Items4.5126.20.156.1—
+ Other — Cash Effects are Investing / Financing-0.0-69.6-1.0-273.0—
Changes in Working Capital
+ Inventories-25.0-79.4-252.513.8—
+ Trade Receivables — Current-123.6-25.1-39.0-20.9—
+ Other Financial Assets — Current0.00.00.00.0—
+ Other Financial Assets — Non-current0.02.00.00.0—
+ Other Current Assets0.0-33.80.00.0—
+ Other Non-current Assets0.040.50.00.0—
+ Trade Payables — Current119.38.7-2.4-201.0—
+ Other Current Liabilities0.0-7.10.00.0—
+ Provisions — Current0.0-8.40.00.0—
Cash from Operating Activities
Profit Before Tax (per I/S)-176.4-61.7154.6292.4350.4
+ Total Adjustments (incl. Working Capital)104.085.4-142.3-281.2—
Cash from Operations (pre-tax)-72.423.812.311.2—
+ Interest Received — Operating-0.5-0.7-2.90.0—
+ Dividends Received — Operating-0.0-0.00.00.0—
+ Income Taxes Paid12.26.416.47.6—
Cash from Operating Activities-85.116.7-7.03.6—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)44.322.5137.4123.0—
+ Disp of Fixed Assets6.48.92.2282.6—
+ Sale of Investments (Equity / Debt)236.565.21.40.0—
+ Acq of Subsidiaries / Businesses (net)0.00.084.50.0—
+ Disp of Subsidiaries / Businesses (net)0.00.00.04.0—
+ Dividends Received — Investing0.00.00.00.0—
+ Interest Received — Investing0.90.61.75.6—
+ Other Inflows / (Outflows) — Investing3.3-1.8-24.622.9—
Cash from Investing Activities202.850.4-241.2192.1—
Cash from Financing Activities
+ Proceeds from Borrowings0.00.0235.275.3—
+ Repayment of Borrowings33.478.525.741.9—
+ Payment of Lease Liabilities3.45.45.96.3—
+ Interest Paid16.322.219.624.9—
+ Dividends Paid28.30.20.30.0—
+ Other Inflows / (Outflows) — Financing0.00.00.0-0.4—
Cash from Financing Activities-81.3-106.3183.81.9—
Net Changes in Cash (pre-FX)36.4-39.2-64.5197.6—
+ Effect of FX Rate Changes on Cash1.86.4-0.72.3—
Net Changes in Cash38.2-32.8-65.2199.9—
Closing Cash183.8150.9———
Reference Items
EBITDA-45.6100.2264.9184.2228.6
EBITDA Margin %-3.395.8812.558.369.90
Free Cash Flow (CFO − Capex)-129.4-5.9-144.4-119.4-119.4
Free Cash Flow to Equity—-106.346.9-105.5—
Free Cash Flow per Basic Share-18.38-0.83-20.51-16.96-16.96
Cash Flow to Net Income0.42-0.24-0.050.01—
Cash Paid for Taxes12.26.416.47.6—
Cash Paid for Interest16.322.219.624.9—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.